Bloch Stephen M sold $14.3M of LQDA (indirect holdings)

Bloch Stephen M sold 220,835 indirectly-held shares of Liquidia Corp (LQDA) at an average of $64.64 ($64.27–$66.19, $14.27M total) across 5 trades over 2026-06-08 to 2026-06-09.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jun 10, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The disclosure provides incremental sentiment information (insider reducing holdings) but lacks any accompanying fundamental update.

02

Market read

Traders may monitor for follow-on insider activity or whether the sale coincides with other company-specific catalysts, but the filing alone is unlikely to drive a major repricing.

03

What to watch

The filing shows indirect ownership and multiple trades; without stated rationale, traders may overinterpret the signal versus broader price/volume trends.

Relevance 7/10Novelty 5/10Timing: Filed 2026-06-10; transactions dated 2026-06-08 to 2026-06-09.

Background

The article reports an SEC Form 4 insider transaction for Liquidia Corp director Stephen M. Bloch.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Liquidia director Stephen M. Bloch sold $14.27M of LQDA shares via open-market transactions (Form 4), reducing insider exposure.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional disclosures or fundamentals.

Evidence & confidence

The article is a primary-source insider transaction (Form 4) with sizable dollar value, but it does not include earnings, guidance, clinical, regulatory, or deal information that would reprice the business.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Director sales can be routine liquidity/portfolio rebalancing and may not reflect negative company outlook, especially without a disclosed 10b5-1 plan context.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider sale disclosure.

  • Stephen M. Bloch

    Director who sold 220,835 shares of LQDA for ~$14.27M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.